



Ciclosporina y metotrexato: Potencial alternativa de tratamiento para la COVID 19

[

2021

text (article)

Analítica

Background: With the presentation of the SARS-CoV-2 pandemic, there is great uncertainty about the effectiveness of the proposed treatments that currently exist and their effectiveness in counteracting the manifestations caused by this virus or, on the contrary, exposing them to patients are at an increased risk of infection or in the worst case, a more severe course of the disease, either from COVID-19 or its underlying pathology. **Methodology:** A narrative review was carried out through various databases from October 2020 to January 2021; the search and selection of articles was carried out in journals indexed in English and Spanish. The following will be used as keywords: SARS-CoV-2, COVID-19, cyclosporine and methotrexate. **Results:** Methotrexate has proven to be an excellent alternative in patients with COVID 19 due to its efficacy, availability, low price, and the extensive experience of this in terms of its use in rheumatoid arthritis, in order to stop the immune response -thrombotic induced by this and support other pathologies associated with COVID 19, such as dermatological and inflammatory lesions. Regarding cyclosporine, it has been proven that the inhibition of the inflammatory pathway of calcineurin, NF-kB, using cyclosporine A (CsA) produces a reduction in the probability of death ratio in hospitalized patients affected by severe COVID-19. **Conclusions:** The present review offers recommendations based on the available evidence about how cyclosporine and methotrexate can become an alternative to combat COVID 19

Background: With the presentation of the SARS-CoV-2 pandemic, there is great uncertainty about the effectiveness of the proposed treatments that currently exist and their effectiveness in counteracting the manifestations caused by this virus or, on the contrary, exposing them to patients are at an increased risk of infection or in the worst case, a more severe course of the disease, either from COVID-19 or its underlying pathology. **Methodology:** A narrative review was carried out through various databases from October 2020 to January 2021; the search and selection of articles was carried out in journals indexed in English and Spanish. The following will be used as keywords: SARS-CoV-2, COVID-19, cyclosporine and methotrexate. **Results:** Methotrexate has proven to be an excellent alternative in patients with COVID 19 due to its efficacy, availability, low price, and the extensive experience of this in terms of its use in rheumatoid arthritis, in order to stop the immune response -thrombotic induced by this and support other pathologies associated with COVID 19, such as dermatological and inflammatory lesions. Regarding cyclosporine, it has been proven that the inhibition of the inflammatory pathway of calcineurin, NF-kB, using cyclosporine A (CsA) produces a reduction in the probability of death ratio in hospitalized patients affected by severe COVID-19. **Conclusions:** The present review offers recommendations based on the available evidence about how cyclosporine and methotrexate can become an alternative to combat COVID 19

Título: Ciclosporina y metotrexato: Potencial alternativa de tratamiento para la COVID 19 [electronic resource]

Editorial: 2021

Tipo Audiovisual: Nefropatía diabética Agonistas del receptor GLP-1 Péptidos similares al glucagón Diabetes mellitus (DeCS) Cyclosporine Methotrexate SARS-CoV-2 COVID-19

Documento fuente: Archivos de medicina, ISSN 1698-9465, Vol. 17, N°. 2, 2021 (Ejemplar dedicado a: Prevención y tratamiento del SARS Cov2)

Nota general: application/pdf

Restricciones de acceso: Open access content. Open access content star

Condiciones de uso y reproducción: LICENCIA DE USO: Los documentos a texto completo incluidos en Dialnet son de acceso libre y propiedad de sus autores y/o editores. Por tanto, cualquier acto de reproducción, distribución, comunicación pública y/o transformación total o parcial requiere el consentimiento expreso y escrito de aquéllos. Cualquier enlace al texto completo de estos documentos deberá hacerse a través de la URL oficial de éstos en Dialnet. Más información: <https://dialnet.unirioja.es/info/derechosOAI> | INTELLECTUAL PROPERTY RIGHTS STATEMENT: Full text documents hosted by Dialnet are protected by copyright and/or related rights. This digital object is accessible without charge, but its use is subject to the licensing conditions set by its authors or editors. Unless expressly stated otherwise in the licensing conditions, you are free to linking, browsing, printing and making a copy for your own personal purposes. All other acts of reproduction and communication to the public are subject to the licensing conditions expressed by editors and authors and require consent from them. Any link to this document should be made using its official URL in Dialnet. More info: <https://dialnet.unirioja.es/info/derechosOAI>

Lengua: Spanish

Enlace a fuente de información: Archivos de medicina, ISSN 1698-9465, Vol. 17, N°. 2, 2021 (Ejemplar dedicado a: Prevención y tratamiento del SARS Cov2)

Baratz Innovación Documental

- Gran Vía, 59 28013 Madrid
- (+34) 91 456 03 60
- informa@baratz.es